PARP inhibitorFDA-approvedInvestigational
Talazoparib
How it works
Blocks the repair of DNA damage in cancer cells, making them more susceptible to chemotherapy and other treatments.
Cancer types
Pancreatic Cancer— BRCA-mutated
Ovarian Cancer— BRCA-mutated
Efficacy
In clinical trials, talazoparib has been shown to improve response rates and progression-free survival in patients with BRCA1/2-mutated ovarian cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Talazoparib and Radiation Therapy for Locally Recurrent Gynecologic Cancers | Ovarian Cancer | phase-1 | — | Source → |
| Study of Talazoparib and Enzalutamide in Men with Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Talazoparib Trial for Advanced Cancer | Breast Cancer | phase-2 | — | Source → |
| New Formulation of Cancer Drug Talazoparib Gets Approval | Prostate Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.